Study of the Safety, Pharmacodynamics, Efficacy, and PK of TIMP-GLIA in Subjects With Celiac Disease
Completed · Phase 2 · Has a placebo group
Conditions studied: Celiac Disease
In brief
Subjects enrolled in this study will be evaluated for immune responses and histological changes in the small bowel following 2 doses of TIMP-GLIA or placebo and a 14-day oral gluten challenge.
Key facts
- Study ID
- NCT03738475
- Run by
- Takeda
- People needed
- 34
- Starts
- 2018-11-11
- Expected to finish
- 2019-07-22
- Last updated by the study team
- 2020-08-12
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Jacksonville Center for Clinical Research — Jacksonville, Florida, United States
- Advanced Clinical Research — Meridian, Idaho, United States
- Indianapolis Gastroenterology Research Foundation — Indianapolis, Indiana, United States
- Beth Isreal Deaconess Medical Center — Boston, Massachusetts, United States
- Mayo Clinic — Rochester, Minnesota, United States
- Prism Clinical Research — Saint Paul, Minnesota, United States
- Rapid Medical Research — Beachwood, Ohio, United States
- Advanced Clinical Research — West Jordan, Utah, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.